Maze Therapeutics Inc. has provided an update on its pipeline focused on kidney and metabolic diseases. The company highlighted progress with its lead program, MZE829, a dual-mechanism APOL1 inhibitor in development for APOL1-mediated kidney disease (AMKD), which disproportionately affects individuals of African ancestry. MZE829 is currently enrolling in a Phase 2 study, with topline proof-of-concept data expected by the end of Q1 2026. The candidate has demonstrated a favorable safety profile and predictable pharmacokinetics in Phase 1 studies, supporting the selection of a 250 mg once-daily dose for further evaluation. Additional programs in the pipeline include MZE782 for phenylketonuria (PKU), with plans to initiate Phase 2 trials by mid-2026, and a chronic kidney disease program expected to enter Phase 2 in the second half of 2026. Maze Therapeutics reports a cash runway extending into 2028 based on its current business plan. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.